Funding
The EMPA-HEART CardioLink-6 trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim. The sponsor had no role in the study design, the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.